Myers, LA, Patel, DD, Puck, JM, Buckley, RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99(3):872–8.CrossRefGoogle ScholarPubMed

Sorror, ML, Maris, MB, Storb, R, Baron, F, Sandmaier, BM, Maloney, DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.CrossRefGoogle ScholarPubMed

Sorror, ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121(15):2854–63.CrossRefGoogle Scholar

Zhang, P, Song, A, Wang, Z, Feng, S, Qiu, L, Han, M. Hematopoietic SCT in patients with a history of invasive fungal infection. Bone Marrow Transplant. 2009;43(7):533–7.CrossRefGoogle ScholarPubMed

Georgiadou, SP, Lewis, RE, Best, L, Torres, HA, Champlin, RE, Kontoyiannis, DP. The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. Bone Marrow Transplant. 2013;48(1):141–3.CrossRefGoogle ScholarPubMed

Kinnebrew, MA, Lee, YJ, Jenq, RR, Lipuma, L, Littmann, ER, Gobourne, A, et al. Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation. PLoS one. 2014;9(3):e90158.CrossRefGoogle ScholarPubMed

Zacharioudakis, IM, Ziakas, PD, Mylonakis, E. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies. Biol Blood Marrow Transplant. 2014.[Epub ahead of print].CrossRefGoogle Scholar

Kumar, D, Humar, A, Plevneshi, A, Siegal, D, Franke, N, Green, K, et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant. 2008;41(8):743–7.CrossRefGoogle ScholarPubMed

Prabhu, RM, Piper, KE, Litzow, MR, Steckelberg, JM, Patel, R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis. 2005;24(12):832–8.CrossRefGoogle ScholarPubMed

Guthrie, KA, Yong, M, Frieze, D, Corey, L, Fredricks, DN. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(4):675–81.CrossRefGoogle ScholarPubMed

Giaccone, L, Festuccia, M, Marengo, A, Resta, I, Sorasio, R, Pittaluga, F, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(6):809–17.CrossRefGoogle ScholarPubMed

Peffault de Latour, R, Lévy, V, Asselah, T, Marcellin, P, Scieux, C, Adès, L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2003;103(5):1618–24.Google ScholarPubMed

Nakasone, H, Kurosawa, S, Yakushijin, K, Taniguchi, S, Murata, M, Ikegame, K, et al. Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. Am J Hematol. 2013;88(6):477–84.CrossRefGoogle ScholarPubMed

Tomblyn, M, Chen, M, Kukreja, M, Aljurf, MD, Al Mohareb, F, Bolwell, BJ, et al. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. Transpl Infect Dis. 2012;14(5):468–78.CrossRefGoogle ScholarPubMed

Tomblyn, M, Chiller, T, Einsele, H, Gress, R, Sepkowitz, K, Storek, J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.CrossRefGoogle ScholarPubMed

Re, A, Michieli, M, Casari, S, Allione, B, Cattaneo, C, Rupolo, M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306–13.CrossRefGoogle Scholar

Krishnan, A, Palmer, JM, Zaia, JA, Tsai, NC, Alvarnas, J, Forman, SJ. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant. 2010;16(9):1302–8.CrossRefGoogle Scholar

Durand, CM, Ambinder, RF. Hematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the potential for viral eradication. Curr Opin Oncol. 2013;25(2):180–6.CrossRefGoogle ScholarPubMed

Hutter, G, Zaia, JA. Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol. 2011;163(3):284–95.CrossRefGoogle Scholar

Dictar, M, Sinagra, A, Veron, MT, Luna, C, Dengra, C, De Rissio, A, et al. Recipients and donors of bone marrow transplants suffering from Chagas’ disease: management and preemptive therapy of parasitemia. Bone Marrow Transplant. 1998;21(4):391–3.CrossRefGoogle ScholarPubMed

Villeneuve, L, Cassaing, S, Magnaval, JF, Boisseau, M, Huynh, A, Demur, C, et al. Plasmodium falciparum infection following allogeneic bone-marrow transplantation. Ann Trop Med Parasitol. 1999;93(5):533–5.CrossRefGoogle ScholarPubMed

Mejia, R, Booth, GS, Fedorko, DP, Hsieh, MM, Khuu, HM, Klein, HG, et al. Peripheral blood stem cell transplant-related Plasmodium falciparum infection in a patient with sickle cell disease. Transfusion. 2012;52(12):2677–82.CrossRefGoogle Scholar

Klein, MB, Miller, JS, Nelson, CM, Goodman, JL. Primary bone marrow progenitors of both granulocytic and monocytic lineages are susceptible to infection with the agent of human granulocytic ehrlichiosis. J Infect Dis. 1997;176(5):1405–9.CrossRefGoogle ScholarPubMed

Goldman, KE. Dental management of patients with bone marrow and solid organ transplantation. Dent Clin North Am. 2006;50(4):659–76, viii.CrossRefGoogle ScholarPubMed

Yamagata, K, Onizawa, K, Yanagawa, T, Hasegawa, Y, Kojima, H, Nagasawa, T, et al. A prospective study to evaluate a new dental management protocol before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38(3):237–42.CrossRefGoogle ScholarPubMed

Elad, S, Thierer, T, Bitan, M, Shapira, MY, Meyerowitz, C. A decision analysis: the dental management of patients prior to hematology cytotoxic therapy or hematopoietic stem cell transplantation. Oral Oncol. 2008;44(1):37–42.CrossRefGoogle ScholarPubMed

George, B, Pati, N, Gilroy, N, Ratnamohan, M, Huang, G, Kerridge, I, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010;12(4):322–9.CrossRefGoogle ScholarPubMed

Chemaly, RF, Ullmann, AJ, Stoelben, S, Richard, MP, Bornhauser, M, Groth, C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370(19):1781–9.CrossRefGoogle ScholarPubMed

Zallio, F, Primon, V, Tamiazzo, S, Pini, M, Baraldi, A, Corsetti, MT, et al. Epstein–Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Clin Transplant. 2013;27(4):E491–7.CrossRefGoogle ScholarPubMed

Kato, K, Kanda, Y, Eto, T, Muta, T, Gondo, H, Taniguchi, S, et al. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant. 2007;13(1):90–9.CrossRefGoogle ScholarPubMed

Pfeiffer, CD, Fine, JP, Safdar, N. diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417–727.CrossRefGoogle ScholarPubMed

Lee, J, Lee, MH, Kim, WS, Kim, K, Park, SH, Lee, SH, et al. Tuberculosis in hematopoietic stem cell transplant recipients in Korea. Int J Hematol. 2004;79(2):185–8.CrossRefGoogle ScholarPubMed

Kobashi, Y, Mouri, K, Obase, Y, Fukuda, M, Miyashita, N, Oka, M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J. 2007;30(5):945–50.CrossRefGoogle ScholarPubMed

Moon, SM, Lee, SO, Choi, SH, Kim, YS, Woo, JH, Yoon, DH, et al. Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis. 2013;15(1):104–9.CrossRefGoogle ScholarPubMed

Onozawa, M, Hashino, S, Darmanin, S, Okada, K, Morita, R, Takahata, M, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant. 2008;14(11):1226–30.CrossRefGoogle ScholarPubMed

Hsiao, LT, Chiou, TJ, Liu, JH, Chu, CJ, Lin, YC, Chao, TC, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12(1):84–94.CrossRefGoogle ScholarPubMed

Lin, PC, Poh, SB, Lee, MY, Hsiao, LT, Chen, PM, Chiou, TJ. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol. 2005;81(4):349–51.CrossRefGoogle ScholarPubMed

Ramos, CA, Saliba, RM, de Padua, Silva L, Khorshid, O, Shpall, EJ, Giralt, S, et al. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(5):686–94.CrossRefGoogle Scholar

Shuhart, MC, Myerson, D, Childs, BH, Fingeroth, JD, Perry, JJ, Snyder, DS, et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood. 1994;84(9):3229–35.CrossRefGoogle ScholarPubMed

Ho, VT, Kim, HT, Aldridge, J, Liney, D, Kao, G, Armand, P, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(8):1196–204.CrossRefGoogle ScholarPubMed

Peffault de Latour, R, Brunstein, CG, Porcher, R, Chevallier, P, Robin, M, Warlick, E, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2013;19(9):1355–60.CrossRefGoogle ScholarPubMed

Bachanova, V, Brunstein, CG, Burns, LJ, Miller, JS, Luo, X, Defor, T, et al. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant. 2009;43(3):237–44.CrossRefGoogle ScholarPubMed

Deeg, HJ, Sandmaier, BM. Who is fit for allogeneic transplantation? Blood. 2010;116(23):4762–70.CrossRefGoogle ScholarPubMed

Xuan, L, Huang, F, Fan, Z, Zhou, H, Zhang, X, Yu, G, et al. Effects of intensified conditioning on Epstein–Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol. 2012;5:46.CrossRefGoogle ScholarPubMed

Roux, E, Helg, C, Chapuis, B, Jeannet, M, Roosnek, E. T-cell repertoire complexity after allogeneic bone marrow transplantation. Hum Immunol. 1996;48(1–2):135–8.CrossRefGoogle ScholarPubMed

Komanduri, KV, St John, LS, de Lima, M, McMannis, J, Rosinski, S, McNiece, I, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007;110(13):4543–51.CrossRefGoogle ScholarPubMed

Lukenbill, J, Rybicki, L, Sekeres, MA, Zaman, MO, Copelan, A, Haddad, H, et al. Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2013;19(5):720–4.CrossRefGoogle ScholarPubMed

Renaud, C, Xie, H, Seo, S, Kuypers, J, Cent, A, Corey, L, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19(8):1220–6.CrossRefGoogle ScholarPubMed

Kim, YJ, Guthrie, KA, Waghmare, A, Walsh, EE, Falsey, AR, Kuypers, J, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195–204.CrossRefGoogle ScholarPubMed

Seo, S, Xie, H, Campbell, AP, Kuypers, JM, Leisenring, WM, Englund, JA, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. Clin Infect Dis. 2014;58(10):1357–68.CrossRefGoogle ScholarPubMed

Wolfromm, A, Porcher, R, Legoff, J, de Latour, RP, Xhaard, A, de Fontbrune, FS, et al. Viral respiratory infections diagnosed by multiplex PCR after allogeneic hematopoietic stem cell transplantation: long-term incidence and outcome. Biol Blood Marrow Transplant. 2014. [Epub ahead of print].CrossRefGoogle Scholar

Abandeh, FI, Lustberg, M, Devine, S, Elder, P, Andritsos, L, Martin, SI. Outcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study. Bone Marrow Transplant. 2013;48(12):1554–7.CrossRefGoogle ScholarPubMed

Kumar, D, Chen, MH, Welsh, B, Siegal, D, Cobos, I, Messner, HA, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis. 2007;45(12):1576–82.CrossRefGoogle Scholar